Mission Therapeutics is a Cambridge-based, clinical-stage biotech focused on harnessing the cell’s natural quality-control process of mitophagy to develop first-in-class therapies for diseases rooted in mitochondrial dysfunction. Their lead compounds include MTX325, aimed at neurodegenerative disorders like Parkinson’s disease, and MTX652, directed at peripheral conditions such as heart and kidney disease, both targeting the deubiquitylating enzyme USP30 to remove the molecular brake on damaged-mitochondria clearance. With strong backing from major life-sciences investors and grants from foundations such as the Michael J. Fox Foundation and Parkinson’s UK, the company is advancing from preclinical success into human proof-of-mechanism trials, signalling a promising shift from symptom management to underlying-cause intervention.